Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Eiji Iwama, Yasushi Goto, Haruyasu Murakami, Taishi Harada, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, Noriaki Nakagaki, Yuka Fujita, Masahiro Seike, Akihiro Bessho, Manabu Ono, Akihito Okazaki, Hiroaki Akamatsu, Ryotaro Morinaga, Shinichiro Ushijima, Takayuki Shimose, Shoji Tokunaga, Akinobu Hamada, Nobuyuki YamamotoYoichi Nakanishi, Kenji Sugio, Isamu Okamoto

研究成果: Contribution to journalArticle

16 引用 (Scopus)

抜粋

Introduction Alectinib has shown marked efficacy and safety in patients with anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement–positive NSCLC and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS. Methods Eligible patients with advanced ALK rearrangement–positive NSCLC and a PS of 2 to 4 received alectinib orally at 300 mg twice daily. The primary end point of the study was objective response rate (ORR), and the most informative secondary end point was rate of PS improvement. Results Between September 2014 and December 2015, 18 patients were enrolled in this phase II study. Of those patients, 12, five, and one had a PS of 2, 3, or 4, respectively, whereas four patients had received prior crizotinib treatment. The ORR was 72.2% (90% confidence interval: 52.9–85.8%). The ORR did not differ significantly between patients with a PS of 2 and those with a PS of 3 or higher (58.3% and 100%, respectively [p = 0.114]). The PS improvement rate was 83.3% (90% confidence interval: 64.8–93.1%, p < 0.0001), with the frequency of improvement to a PS of 0 or 1 being 72.2%. The median progression-free survival was 10.1 months. Toxicity was mild, with the frequency of adverse events of grade 3 or higher being low. Neither dose reduction nor withdrawal of alectinib because of toxicity was necessary. Conclusions Alectinib is a treatment option for patients with ALK rearrangement–positive NSCLC and a poor PS.

元の言語英語
ページ(範囲)1161-1166
ページ数6
ジャーナルJournal of Thoracic Oncology
12
発行部数7
DOI
出版物ステータス出版済み - 7 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

フィンガープリント Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Okazaki, A., Akamatsu, H., Morinaga, R., Ushijima, S., Shimose, T., Tokunaga, S., Hamada, A., ... Okamoto, I. (2017). Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401). Journal of Thoracic Oncology, 12(7), 1161-1166. https://doi.org/10.1016/j.jtho.2017.02.012